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Abstract 
 
Mechanistic target for rapamycin (mTOR) is a serine/threonine protein kinase that forms two distinct 
complexes mTORC1 and mTORC2, integrating mitogen and nutrient signals to regulate cell survival 
and proliferation; processes which are commonly deregulated in human cancers. mTORC1 and 
mTORC2 have divergent molecular associations and cellular functions: mTORC1 regulates in mRNA 
translation and protein synthesis, while mTORC2 is involved in the regulation of cellular survival and 
metabolism. Through AKT phosphorylation/activation, mTORC2 has also been reported to regulate cell 
migration. Recent attention has focused on the aberrant activation of the PI3K/mTOR pathway in B cell 
malignancies and there is growing evidence for its involvement in disease pathogenesis, due to its 
location downstream of other established novel drug targets that intercept B cell receptor (BCR) signals. 
Shared pharmacological features of BCR signal inhibitors include a striking “lymphocyte redistribution” 
effect whereby patients experience a sharp increase in lymphocyte count on initiation of therapy 
followed by a steady decline. Chronic lymphocytic leukemia (CLL) serves as a paradigm for migration 
studies as lymphocytes are among the most widely travelled cells in the body, a product of their role in 
immunological surveillance. The subversion of normal lymphocyte movement in CLL is being 
elucidated; this review aims to describe the migration impairment which occurs as part of the wider 
context of cancer cell migration defects, with a focus on the role of mTOR in mediating migration effects 
downstream of BCR ligation and other microenvironmental signals. 
 
 
 
Highlights 
 
 mTOR forms two distinct complexes mTORC1 and mTORC2, responsible for integrating 
mitogen and nutrient signals to regulate cell survival, proliferation and migration; processes 
which are commonly deregulated in human cancers.  
 In this review we summarize the role played by mTOR kinase in regulating migration, using 
chronic lymphocytic leukemia as a paradigm for migration studies. 
 BCR-signaling antagonists in combination with dual mTOR inhibitors may provide a novel 
therapeutic strategy for overcoming drug resistance in B cell malignancies. 
  
mTOR-mediated signaling 
Mechanistic target for rapamycin (mTOR) resides in two distinct signaling complexes mTORC1 and 
mTORC2, which integrate growth factor and nutrient signals to promote cell survival, growth and 
proliferation (1). mTORC1 contains RAPTOR, mLST8, PRAS40 and DEPTOR and mTORC2 contains 
RICTOR, mLST8, mSIN1 and DEPTOR (1-4). Originally defined in yeast (5, 6), the 250kDa protein 
kinase is both growth factor- and nutrient-sensitive with respect to mTORC1 however the “rapamycin-
insensitive” mTORC2 responds only to growth factor signals and its existence explains the evident 
mTOR activity upon treatment with rapamycin (7). Positioned downstream of the phosphatidylinositol-3-
kinase (PI3K)-mediated signaling, mTOR integrates signals from binding of chemokine receptors, such 
as CXCR4 and CXCR5, and BCR-mediated signals in addition to the more frequently reported 
metabolic and growth factor responses ((8) & Figure 1). The tuberous sclerosis (TSC1-TSC2) protein 
complex acts as an intermediary between the PI3K/AKT and mTOR signal, and its phosphorylation by 
AKT causes disassociation of the complex from GTPase Rheb which permits mTOR activation (9). 
Alternatively, in conditions of oxidative stress, hypoxia or starvation, mTOR may be inhibited by TSC1/2, 
activated by the conversion of Rheb-GTP to Rheb-GDP by 5’adenosine monophosphate-activated 
protein kinase (AMPK). While mTORC1 phosphorylates p70S6kinase (S6K) and eukaryotic initiation 
factor 4E-binding protein 1 (4EBP1) to increase protein synthesis, mTORC2 directly phosphorylates 
AktS473, enhancing its kinase activity 5 – 10 fold to promote cell survival and initiate cell cycle (10, 11). 
Through AKT regulation, mTORC2 is considered to play a role in migration, however the precise 
molecular mechanisms have yet to be elucidated (11, 12). 
 
The activation of mTORC1 may be further regulated by localization of the complex; mTOR is largely 
cytoplasmic but can associate with cellular organelle membranes, affecting its ability to phosphorylate 
S6K1. The functions of mTORC1 involve regulation of cellular proliferation, cell size, ribosomal 
biogenesis and angiogenesis by phosphorylation of S6K1 and 4E-BP1, which are directly responsible 
for mRNA translation (13). After mTORC1 activation, S6K1 triggers protein synthesis by 
phosphorylating PDCD4, marking it for degradation with secondary effects of binding and preventing 
elF4A helicase from fulfilling its function in mRNA unwinding. S6K1 can also function to dampen 
signaling via PI3K by inhibition of insulin receptor substrate 1 (IRS1) and 2 (IRS2) expression, providing 
a negative feedback loop within the mTORC1 side of the complex, thus explaining the non-aggressive 
nature of the hamartomatous tuberous sclerosis syndrome, a product of mutations in tsc1/2 (14). Upon 
phosphorylation by mTORC1, 4E-BP1 is released from inhibiting the elongation initiation factor 4E 
(eIF4E).  
 
mTORC2 plays a major role in signaling via the PI3K/AKT pathway, through phosphorylation and 
activation of AKT making it of interest as a therapeutic target in blocking the AKT signal, as mTORC2 
has been demonstrated to be necessary for the development of activated PI3K signaling in tumors (15). 
Of note, an inhibitory feedback loop exists between mTORC1 and mTORC2, enabling an upregulation 
in AKT signaling with the removal of the mTORC1 signal, suggesting a complex regulatory role for 
mTOR in AKT-dependent malignancies (16, 17). 
 
mTOR regulation of migration 
To delineate the relative contribution of mTOR complexes to the cellular migration process we still refer 
to evidence from studies utilizing rapamycin. The regulation of migration by inhibition of S6K1 and 
4EBP1 has been shown in a variety of cell types, by the administration of rapamycin, to delineate the 
mechanisms by which control is exerted, including formation of the F-actin cytoskeleton, extracellular 
matrix remodeling (e.g. MMP9) focal adhesion formation, and Rho GTPase activation all regulated via 
S6K1 (18-20). Furthermore, there is evidence derived from inhibitor studies that support both mTORC1 
and mTORC2 as regulators of cell adhesion (21). Extracellular matrix changes and GTPase activity are 
also regulated by 4EBP1 with evidence that it regulates VEGF/TGF levels in a rapamycin-sensitive 
manner in mouse models of solid organ tumors and metastasis (22). Rapamycin appears to exert its 
effect downstream of S6K1 and 4EBP1 via regulation of small GTPase RhoA activation (23).  In 
contrast, mTORC2 mainly modulates the actin cytoskeleton to regulate migration (24, 25). Downstream 
effectors appear to be species and cell-type specific. PKA and Ras signaling pathways appear to be 
pivotal in amoebae (26), while, in mammals PKC, PKA signaling and Rac/RhoA are the main regulators 
of mTORC2-mediated migration (27). Studies using amoebae demonstrate that TORC2 exerts its 
influence via AKT and PKA regulation of adenylyl cyclase –based production of cyclic AMP (28). In 
mammalian systems, it appears that mTORC2 regulates neutrophil chemotaxis by regulation of F-actin 
polarization and myosin II phosphorylation, again regulated by cAMP production but via PKC in a 
RhoA/ROCK dependent fashion (29). There are also putative mTORC2-independent effects of RICTOR 
on migration that have yet to be fully explored (30).  
 
It is hypothesized that mTORC1/2 inhibitors would also have effects on cytoskeletal formation with 
downstream effects of cAMP production mediated by PKC and GTPases and this is supported by 
studies from a variety of model organisms and cell types. Indeed, the first description of the RICTOR 
homologue pianissimo in Dictyostelium discoidieum is as a regulator of chemokine and GTPase signals. 
In the described piaA knock-out model, cells are unresponsive to chemokine stimulation or GTPS 
activation, defects that are restored with constitutive activation of piaA (31). Cytoskeletal regulation was 
attributed to TORC2 in Saccharomyces cerevisiae and amoebae through regulation of the Rho GTPase 
family and downstream mediators including pkc1 (32). In mammalian systems, a link between RICTOR 
and PKCwas established first (25) followed by a link between mTORC2 and RhoA family in regulation 
of neutrophil chemotaxis via mechanisms which are independent of actin cytoskeletal reorganization 
(33). It appears that Rac/cdc42 GTPases are responsible for actin cytoskeleton formation and these 
effects are driven by RICTOR-mediated inhibition of Rho-GDP dissociation inhibitor 2 (29, 34). 
 
CLL and migration 
Cancer cell rehoming and the mechanisms by which it is governed are central to tumor spread and 
clonal expansion (35). The processes of cytoskeletal protein assembly, actin remodeling and integrin 
formation are amongst a range of individual events that precede cellular migration and are tightly 
regulated by chemokine and adhesion molecule interactions. In normal lymphocyte migration, selectin 
and integrin binding of lymphocytes at the vascular endothelium initiates lymphocyte rolling, arrest and 
firm adhesion. Subsequent transendothelial migration is triggered by integrin activation and chemokine 
receptor/ ligand binding as the lymphocyte is exposed to local chemokine release from the vascular 
lumen (36). B cell positioning within the lymph node (LN) germinal center is determined by chemokine 
surface receptor expression of CXCR4 and CXCR5 and secretion of ligands CXCL12, CXCL13 and 
CCL19/CCL21 by the LN stromal cells. B cells migrate along chemokine gradients to the appropriate 
microanatomical site where they mature through phases of somatic hypermutation and clonal selection 
on the basis of antigen affinity (35).  
 
In CLL, the pathophysiological process hijacks the innate properties of normal B cells not only to retain 
the function of recognized surface markers which interact with chemokines to regulate migration such 
as CXCR4 – CXCL12 and CXCR5 – CXCL13, but also to utilize the enhanced expression of these 
markers, facilitating increased migration to the secondary lymphoid organs.  Understanding the 
regulation of these events offers potential candidates for in vitro study of oncogenic signaling: molecules 
of interest in CLL can be broadly categorized as chemokine receptors, adhesion molecules and other 
transmembrane signaling molecules. CXCR4 surface molecule function is preserved in CLL cells with 
high expression of CXCR4 on CLL cells in peripheral blood and downregulated expression after 
migration underneath a stromal cell layer (37). Also, CXCR5 surface expression is found to be present 
and functional on CLL cells (38). The molecule CD49d, which is the 4 component of the 41 integrin 
complex, has been implicated in CLL cell migration for some time (39) and its expression has been 
found to co-segregate with prognostic entities that have a tendency for increased migration (40, 41). 
Interestingly, those cells carrying trisomy 12 in association with the poor prognostic marker NOTCH1 
mutation display further upregulation of integrin signaling by way of increased 2 signaling (40). The 
surface marker CD38 is established as a marker of negative prognostic significance and this could be in 
part due to increased BCR signaling and tendency for cellular migration to the LN (42). CD44 interaction 
with its extracellular matrix ligand hyaluronan (HA) plays a role in cell positioning within the secondary 
lymphoid organs to receive pro-survival signals, which have been implicated in cell activation, migration 
and tissue retention of CLL cells. Properties of the CLL microenvironment including the presence of 
CCL21 secretion and the strength of CD40-CD40L interactions with T cells determine the balance of the 
equilibrium of CD44-HA binding; CCL21 induces motility whereas CD40L stimulation shifts the balance 
towards tissue retention of CLL cells (43). The surface receptor CD62L is implicated in homing of CLL 
cells and is upregulated in cells localized to LN and BM tissue (44). A similar pattern of increased 
expression of MMP9 on cells localized to the LN and BM formed the basis of studies of MMP9 in CLL 
migration and invasion. In vitro modeling of migration demonstrated an upregulation in MMP9 with 
increased migration under regulation by 41 integrin and PI3K/AKT signaling (45). 
 
GTPases are also dysregulated in CLL cell migration, elucidated by two studies with a specific focus on 
the role of Rap1 GTPase. Chemokine-induced transendothelial migration has been shown to be 
defective in CLL and pathological B cells lose their chemokine-responsiveness in the disease. GTP-
loading of Rap1 fails due to impaired endosomal recycling to the plasma membrane and this has been 
attributed to defective activation of phospholipase D1 and Arf1, its regulator (46). Additionally, 
chemokine-induced activation of integrin clustering fails due to an inability of polar clustering of L2 
integrin which is Rap1- induced. Binding of 41, VEGF and chemokine are all needed for L2 
activation, as a result of failure to GTP-load Rap1 in CLL cells (47).  
 
More recent studies of cellular migration have described surface changes in chemokine receptor profile 
and have derived an emigrant lymphocyte phenotype (CXCR4dim/CD5hi) (48). Proliferation studies have 
established a 2-compartment model of CLL with those cells in the peripheral blood demonstrating a low 
proliferation rate and those with a higher birth rate being derived from the secondary lymphoid tissue. 
Cells traffic between compartments and display distinct surface immunophenotype along with gene 
expression profile (49). Studies that demonstrate the immunophenotypic differences employed 
deuterium labeling of resting and proliferative fractions of CLL cells (50) whereas later work examined 
paired fine needle aspirates and peripheral blood CLL samples and used functional assays to 
demonstrate phenotypic differences. An in vitro circulation system of migration was utilized to lend 
further support to the proposed model of migration in which the CLL microenvironment exerts a 
phenotype upon cells according to their positioning (48). 
 
BCR signal transduction and migration 
Further evidence for migratory effects as part of the neoplastic process can be derived from recent 
advances in CLL therapy and the function of inhibitors which act downstream of the BCR signaling 
cascade. It has long been understood that the ability of B cells to respond to antigenic binding of BCR 
molecules is retained in CLL but the reliance on differential methods of activation of signaling 
downstream of the BCR varies by B cell malignancy. Both antigen-dependent and autonomous BCR 
signaling are at play in CLL and recruit similar downstream effectors in signal mediation. Antigen 
binding of the BCR molecule, through the surface immunoglobulin (sIg) leads to Ig/(CD79a/b) 
phosphorylation of tyrosine residues on immune-receptor tyrosine-based activation motifs (ITAMs) by 
Src-family kinases, such as LYN, FYN or BLK. Binding of tandem Src homology 2 (SH2) domains within 
the spleen tyrosine kinase (SYK) molecule, a non-receptor tyrosine kinase, allows further propagation of 
the signal by recruitment of BLNK to the phosphorylated tyrosine residues. BLNK, the B cell linker 
protein also known as SLP-65, acts as a substrate for SYK to recruit proteins such as the enzyme 
phospholipase C gamma 2 (PLC2) and TEC family kinase Bruton’s tyrosine kinase (BTK) to the 
signaling complex (Figure 1). Active PI3K generates phosphatidylinositol (3,4,5) triphosphate (PIP3) to 
enable membrane recruitment of oncogenic serine/threonine kinase AKT, BTK and PLC2 and permit 
signal transduction to the nucleus. The PI3K family of enzymes comprises three classes, regulating cell 
growth, differentiation and survival. Class IA PI3K are dysregulated in human disease, including the 
isoform PI3K whose expression is restricted to hematopoietic cells and implicated in the pathogenesis 
of B cell malignancies (51).  
The impact of BCR signaling inhibitors on CLL migration 
Ibrutinib, fostamatinib and idelalisib, which target BTK, SYK and PI3K respectively, all affect CLL cell 
migration mediated by tissue-specific expression of chemokines and ligands; modulating processes of 
cellular adhesion, transendothelial migration and tissue retention via effects on integrins and adhesion 
molecules (52-54). These inhibitors, as well as targeting BCR-mediated signals, also have effects on 
microenvironmental signaling outwith the BCR signaling pathway. Paracrine secretion of chemokines 
CCL3 and CCL4 by CLL cells is blocked, reducing support from monocyte-derived nurse-like cells and 
accessory T cells (52, 53). Pre-clinical studies of BCR signaling inhibitors detail a striking lymphocytosis 
effect with individual therapies in terms of plasma chemokine levels and surface receptor expression. 
Using primary CLL samples De Rooij et al. demonstrated a reduction in signaling via CXCL12, CXCL13 
and CCL19 upon ibrutinib treatment, with a reduction in adhesion and migration of CLL cells (54). In 
parallel studies of ibrutinib, Ponader et al. identified a reduction in migration toward CXCL12 and 
CXCL13, which inhibited CCL3 and CCL4 secretion. Targeting of SYK with fostamatinib also displayed 
an inhibitory effect on CCL3 and CCL4 secretion in primary disease samples, with a reduction in homing 
towards CXCL12 and CXCL13 and a reduction in CLL cell adhesion to VCAM-1 (53, 55). Our group 
investigated the effects of LYN kinase inhibition with dasatinib revealing inhibitory effects on the 
CXCR4-CXCL12 signaling axis in CLL samples in vitro (56). PI3K inhibition with idelalisib revealed a 
downregulation of chemokine levels in vitro, a finding that was corroborated by data from patients 
treated with the drug during clinical trial. Chemokine levels in patient plasma samples exhibited a 
reduction in secretion of CCL3, CCL4 and CXCL13 and a concomitant surge in the lymphocyte count in 
the peripheral blood (52). 
 
The TCL-1-transgenic mouse model develops a leukemia analogous to poor prognostic CLL, due to the 
overexpression of the oncogene T cell leukemia/lymphoma 1 (TCL-1) in B lineage cells (57), and has 
been used to delineate the molecular mechanisms that govern CLL cell migration. Pre-clinical data 
using ibrutinib and fostamatinib in these mice showed in vivo effects of an initial increase in 
lymphocytosis with therapy and a reduction in lymphadenopathy (58, 59). In studies with TCL-1 mice, 
dasatinib was found to have inhibitory effects on LYN substrate hematopoietic lineage cell-specific 
protein 1 (HS1) which has targeted effects on regulation of migration via cytoskeletal formation (60). 
Further work to elucidate the mechanisms of migration control reveal that the TCL-1 GTPase Rho 
knockout model displays a delayed disease onset, with a reduction in homing of cells to the BM, a 
reduction in interactions with CXCL12 and CXCL13 and a reduction in the polarization of 
phosphorylated focal adhesion kinase (FAK) with defective integrin function (61). 
 
Targeted inhibition of mTOR complexes 
mTOR kinase was discovered by virtue of research gaining an understanding of the pharmacological 
activity of rapamycin (62). Originally discovered in the soil of Easter Island and derived from 
Streptomyces Hygropicus, this macrolide was found to possess both immunosuppressive and anti-
neoplastic properties (63, 64). The two mTOR complexes are defined by their differential responses to 
rapamycin; mTORC1 binds rapamycin allosterically by its association with FKBP12 whereas mTORC2 
was first thought to be rapamycin-insensitive thus making mTORC1 the obvious choice as a drug 
development target. Thereafter, CCI-779 (temsirolimus) and RAD001 (everolimus) which have greater 
clinical tolerability than rapamycin, were developed for clinical use and have been trialed as therapies in 
both solid organ and hematological cancers with some efficacy (65-68). In CLL, everolimus elicited 
similar lymphocyte redistribution effects to that of PI3K and BTK inhibitors however overall clinical 
responses were not as promising (68), potentially due the existence of the negative feedback loop 
allowing preservation of AKT signaling in the absence of mTORC1 signal (16, 17).  
 Dual mTOR inhibitors can be divided into two broad categories (Table 1). Firstly, there are small 
molecules that selectively inhibit both mTORC1 and mTORC2. First-in-class drug AZD8055 and its 
formulation for clinical use AZD2014 (Vistusertib) is an ATP-competitive inhibitor of mTOR, which 
selectively blocks phosphorylation of mTOR substrates (69). Dual mTOR inhibitors are ATP-competitive 
inhibitors and their superior clinical results and depth of mTORC1/2 inhibition was originally attributed to 
their ability to inhibit mTORC2 however some of their properties may a result of their ability to block 
rapamycin-resistant components of mTORC1. Upon inhibition of PRAS40 phosphorylation by dual 
mTOR inhibitors, this protein has enhanced binding of the RAPTOR/mTOR complex with resultant 
inhibition of the mTORC1/4EBP1 signal (70). Furthermore, there are differential effects upon cyclin D1 
and D3 by rapamycin and dual mTOR inhibitors, with a reduction in protein expression of these and an 
increase in p27 with dual mTOR inhibition (71). Pitfalls with these agents include the existence of 
alternative activating signals or negative feedback loops. Other types of dual mTOR inhibitor aim to 
overcome the potential deficiencies of specific inhibitors and inhibit PI3K signals as well as mTOR 
(Table 1); these have the advantage of inhibiting the three proto-oncogenic kinases PI3K, AKT and 
mTOR, closing some of the feedback loops. The pan PI3K/mTOR inhibitor SAR245409 (voxtalisib) was 
demonstrated to inhibit BCR-mediated adhesion to a similar extent as idelalisib, while the 
PI3Kinhibitor was less effective, supporting a key role for PI3K in regulating CLL adhesion. 
SAR245409 was also shown to partially reduce chemokine-mediated migration in CXCL12-transwell 
migration studies, with a modest but significant reduction in migration (72). The pan PI3K/mTOR 
inhibitor PF-04691502 exhibited significant inhibition of BCR- and CXCR4-mediated signaling, and 
potent reduction in migration towards CXCL12 in transwell assays (73). Furthermore, PF-04691502 
induced a lymphocytosis in TCL-1 mice, and blocked leukemia development in these mice, similar to 
that observed in TCL-1 mice treated with ibrutinib and fostamatinib (58, 59, 73). Therefore, pan 
PI3K/mTOR inhibitors have fared well in pre-clinical tests in CLL and clinical data is awaited. To 
augment the approach to mTOR inhibition further CC-115, a dual mTOR/DNA-PK inhibitor has shown 
promise in vitro inducing more robust caspase-dependent cell killing, and inhibition of proliferation and 
BCR-mediated signaling in comparison to specific mTOR inhibitor CC-214 and BTK inhibitor CC-292. 
CC-115 has progressed further to preliminary clinical testing, with promising early clinical results, with 
the majority of patients exhibiting decreased lymphadenopathy (74). 
 
Conclusion 
Cellular migration is appropriated by neoplastic processes and in CLL there are demonstrable changes 
in the cellular phenotype which determine cell localization. As a consequence of these changes, cells 
may be encouraged to proliferate with subsequent clonal expansion and evolution.  The molecular 
mechanisms that mediate the effects on migration are not fully understood however insights may be 
gained from knowledge of recent advances in CLL therapeutics. The pathway at the center of this 
review, mTOR signaling, is described and evidence is provided in support of mTOR inhibition as a 
means of controlling CLL cell migration. Theories as to the suboptimal clinical performance of mTORC1 
inhibition include the incomplete block of the pathway or the existence of negative feedback loops. 
There is a need for in vitro study of dual mTORC1/2 inhibition in CLL incorporating all emerging data on 
crosstalk between mTOR and other signaling pathways to optimize experimental design. Synergistic 
studies utilizing PI3K and BTK inhibitors alongside dual mTOR inhibitors may provide a basis for clinical 
trial designs in the use of combination therapy to overcome drug resistance. 
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Compound Target Phase Disease Reference 
AZD2014 
(Vistusertib) 
mTORC1/2 I-II AST, GBM, HCC, 
Lymphomas 
(69) 
MLN0128 
(TAK228) 
mTORC1/2 I-II Prostate, thyroid, 
breast, liver 
Hsieh et al., Nature 
(2012) 
OSI-027 mTORC1/2 I AST, Lymphomas Mateo et al., Br J 
Cancer, 2016 
CC-223 mTORC1/2 I-II NSCLC, NHL, 
MM 
Bendell et al., Cancer 
(2015) 
PF-04691502 PI3K-mTORC1/2 I-II Breast, 
Endometrial, AST 
(73) 
VS-5584 PI3K-mTORC1/2 I Metastatic cancer, 
lymphoma 
Hart et al., Mol Cancer 
Ther (2013) 
SAR245409 
(Voxtalisib) 
PI3K-mTORC1/2 I-II AST, GBM, 
Ovarian, Breast 
Awan et al. Br J Haem 
(2016) 
CC-115 mTORC1/2 & DNA-
PK 
I-II AST, GBM, AML (74) 
 
Table 1: Table of dual mTOR inhibitors in current clinical trials 
Key: AST = Advanced Solid Tumors, GBM = Glioblastoma Multiforme, HCC= Hepatocellular 
Carcinoma, AML = Acute Myeloid Leukemia, NSCLC= Non-Small Cell Lung Cancer, NHL = Non-
Hodgkin Lymphoma 
 
 
 
 
  
  
Figure 1: Diagram of B cell receptor signal transduction cascade and mTOR mediated 
components within normal B cells. The mTOR kinase complex is positioned downstream of the BCR 
and chemokine (CXCR4-CXCL12) receptors. The mTORC1 and dual mTORC1/2 inhibitors, rapamycin 
(Rapa) and AZD8055/AZD2014 respectively, are shown with their site of action within the mTOR 
cascade.  
 
